Frequency and antimicrobial susceptibility of Shigella species isolated in Children Medical Center Hospital, Tehran, Iran, 2001-2006  by Pourakbari, Babak et al.
O
R
IG
IN
A
L 
 
A
R
TI
CL
E
153
Frequency and antimicrobial susceptibility of Shigella species 
isolated in Children Medical Center Hospital, Tehran, Iran, 
2001-2006
Authors
Babak Pourakbari1,2
Setareh Mamishi, MD2
Negar Mashoori3
Nastaran Mahboobi3
Mohammad H Ashtiani4
Shahla Afsharpaiman5
Masomeh Abedini6
1Pediatrics Infectious 
Diseases Research Center, 
Tehran University of Medical 
Sciences, Tehran, Iran. 
2Department of Infectious 
Disease, School of Medicine, 
Tehran University of Medical 
Sciences, Tehran, Iran. 
3School of Medicine, Tehran 
University of Medical 
Sciences, Tehran, Iran. 
4Department of Pathology, 
School of Medicine, Tehran 
University of Medical 
Sciences, Tehran, Iran. 
5Department of Pediatrics, 
School of Medicine, 
Sanandaj University of 
Medical Sciences, Tehran, 
Iran. 
6Department of Pediatrics, 
School of Medicine, 
Baghiatallah University of 
Medical Sciences, Tehran, 
Iran. 
Submitted on: 05/23/2009
Approved on: 08/18/2009
Correspondence to: 
Setareh Mamishi, MD
Department of Pediatrics 
– Infectious Disease 
Children Medical Center 
Hospital
Medical Sciences/
University of Tehran
No. 62, Gharib St., 
Keshavarz Blvd.
Tehran – Iran
Phone: 98 021 6428996
Fax: 98 021 6428996
E-mail: smamishi@sina.
tums.ac.ir
We declare no conﬂ ict of 
interest.
ABSTRACT
Appropriate antimicrobial treatment of shigellosis depends on identifying its changing resistance 
pattern over time. We evaluated 15,255 stool culture submitted from July 2001 to June 2006 to the 
Laboratory of Children Medical Center Hospital. Specimen culture, bacterial identifi cation, and disk 
diffusion susceptibility testing were performed according to National Committee for Clinical Labo-
ratory Standards guidelines. From 15,255 stool samples, 682 (4.5%) were positive for Shigella spe-
cies. The most common species of Shigella were S. ﬂ exneri (48%) and S. sonnei (45%); other results 
were S. dysenteriae (5%) and S. boydii (2%). The rate of Sensitivity to ceftriaxone (95%), ceftizoxime 
(94%), and nalidixic acid (84%) were among our isolates. Resistance to co-trimoxazole and ampicil-
lin was 87% and 86%, respectively. S. ﬂ exneri was more multiresistant than other species (47.9%). 
Our isolates are overall most sensitive to ceftriaxone, ceftazidime, and nalidixic acid (> 84%). They 
were most resistant to co-trimoxazole and ampicillin (> 86%). Because resistance varies according to 
specifi c location, continuous local monitoring of resistance patterns is necessary for the appropriate 
selection of empirical antimicrobial therapy.
Keywords: Shigella, antimicrobial susceptibility, dysentery.
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INTRODUCTION
Dysentery caused by Shigella species is called 
shigellosis, which is one of the most common 
causes of dysentery in children. It is responsible 
for increased cases of morbidity and mortality 
in developing countries. Global studies suggest 
there are 164.7 million episodes of shigellosis 
per year, of which 163.2 million were in devel-
oping countries, and 1.5 million in developed 
countries. These episodes result in 1.1 million 
deaths, of which two-thirds occur in children 
under 5 years of age.1
The epidemiology and antibiotic suscep-
tibility of Shigella species changes over time. 
Treatment of shigellosis by appropriate anti-
microbial agents has proven to be effective in 
shortening the duration of fever, diarrhea and 
toxemia, and apparently in reducing the risk of 
lethal complications as well. Also, the excretion 
of pathogen in stool is shortened signifi cantly, 
reducing the spread of infection.2 Appropri-
ate antibiotic treatment of shigellosis depends 
on identifying resistance patterns. So, updated 
knowledge of Shigella susceptibility is neces-
sary for appropriate empirical antibiotic treat-
ment. In this study, we assessed the frequency 
of Shigella species and their antimicrobial re-
sistance at Children’s Medical Center (CMC) 
Hospital between July 2001 and June 2006. The 
aims of this study were to analyze antimicro-
bial resistance of Shigella isolates to suggest 
timely recommendations for empirical antibi-
otic therapy.
MATERIAL AND METHODS
Source of specimens
We evaluated 15,255 stool culture submitted 
from July 2001 to June 2006 to the Laboratory 
of CMC Hospital. Only one Shigella isolate per 
patient per diarrheal episode was included in 
the analysis. All the included patients lived in 
Tehran at the time of study and they were not 
hospitalized or received any antibiotic during 
the month before presentation with shigellosis. 
In addition to being a referral tertiary care cen-
tre, CMC Hospital is one of the educational hos-
pitals of Tehran University of Medical Sciences. 
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Microbial examination
Stool specimens were cultured on Salmonella-Shigella 
(SS) Agar and Eosin methylene blue (EMB) agar and in-
cubated at 37° C for 1 to 5 days. Biochemical tests were 
done by standard methods on grown bacteria to identify 
Shigella species, which grouped serologically by slide ag-
glutination with specifi c antisera. Antibiotic susceptibil-
ity to ceftazidime, tobramycin, ceftizoxime, ceftriaxone, 
chloramphenicol, kanamycin, nalidixic acid, cephalothin, 
co-trimoxazole, ampicillin, gentamicin and amikacin was 
determined in all specimens by disc diffusion method ac-
cording to the National Committee for Clinical Laboratory 
Standards (NCCLS).3 To verify that susceptibility test re-
sults were accurate, we used E. coli ATCC 25922 as con-
trol strain according NCCLS guideline.3 The antimicrobial 
agents selected for analysis were those commonly included 
in the treatment of shigellosis in Iran. Results were inter-
preted according to NCCLS guidelines as either sensitive, 
intermediate, or resistant.4 In our study, we considered 
both intermediate and resistant as resistant. Isolates were 
considered multiresistant if they were resistant to ampicil-
Table 1. Frequency of Shigella species isolated from 
stool cultures of patients at Children Medical Center 
Hospital, Tehran, Iran
Shigella species Frequency Percent
S. flexneri 190 47.9
S. sonnei 179 45.1
S. dysenteriae 20 5.0
S. boydii 8 2.0
Total 397 100.0
lin and co-trimoxazole.5 Antimicrobial susceptibility re-
sults were rounded down if < 0.5 and were presented as 
whole numbers if ≥ 0.5.
Statistical analysis
The signifi cance of differences in proportions of antimi-
crobial resistance of Shigella species was determined by the 
chi-square test or the Fisher Exact test (when the expected 
value in > 20% of the cells was < 5). P-value < 0.05 was con-
sidered statistically signifi cant. Statistical calculations were 
performed with SPSS statistical software (version 13.0; SPSS 
Inc., Chicago, IL, USA).
 
RESULTS
From 15,255 stool samples, 682 (4.5%) were positive for 
Shigella species. The species of 397 out of 682 Shigella iso-
lates were determined. The most common species of Shigella 
was S. ﬂ exneri (48%) and S. sonnei (45%), and other results 
were S. dysenteriae (5%) and S. boydii (2%) (Table 1). Shigel-
la isolates were totally most sensitive to ceftriaxone (95.4%), 
ceftizoxime (94%), and nalidixic acid (83.5%); and most re-
sistant to co-trimoxazole (87%) and ampicillin (86%). All 
results are shown in Table 2. S. ﬂ exneri was most sensitive to 
Ceftriaxone (94%), Ceftizoxime (90%), and Nalidixic acid 
(89%); and most resistant to Ampicillin (96%) and Co-tri-
moxazole (90%). Comparing the results of susceptibility by 
year over the study period, it was found increase of rates of 
resistance to cefazolin, cefi xime, tobramycin, amikacin in S. 
ﬂ exneri isolates (p-value < 0.05). S. sonnei was most sensitive 
to ceftizoxime (98%), ceftriaxone (97%), and chlaromphen-
icol (93%); and most resistant to co-trimoxazole (92%) and 
ampicillin (73%). These isolates comparing the results of 
susceptibility by year showed increase of rates of resistance 
Table 2. In vitro antimicrobial susceptibility of Shigella species isolated from stool cultures at Children Medical 
Center Hospital, Tehran, Iran 
Antibiotics                       Sensitive                             Resistant
 n valid percent n valid percent
Chloramphenicol 308 67% 134 30%
Nalidixic acid 543 84% 107 16%
Tobramycin 486 80% 112 20%
Gentamicin 537 82% 121 18%
Amikacin 530 82% 115 18%
Kanamicin 235 40% 358 60%
Ampicillin 94 14% 577 86%
Co-trimoxazole 83 12% 581 88%
Cephalotine 374 58% 276 42%
Ceftizoxime 586 94% 40 6%
Ceftazidime 312 73% 118 27%
Ceftriaxone 596 95% 29 5%
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to kanamycin, cefalotin, ampicillin, gentamycin, amikacin, 
ceftriaxone, ceftazidime, tobramycin (p-value < 0.05). S. 
dysenteriae was completely sensitive to ceftriaxone, cefti-
zoxime, cephalotine, co-trimoxazole (100%), and it was 
most resistant to kanamycin (100%), amikacin (63%), and 
nalidixic acid (63%). S. boydii was totally sensitive to gen-
tamicin, amikacin, ceftriaxone, ceftizoxime, ceftazidime, and 
tobramycin (100%); and most resistant to co-trimoxazole 
(75%), cephalotine (75%), ampicillin (63%), and kanamy-
cin (60%) (Table 3). In S. dysenteriae and S. boydii isolates 
were not seen any valuable signifi cance in rate of resistance 
when comparing the results by the years. Among 682 iso-
lates, 500 isolates were multiresistant (74%). S. ﬂ exneri was 
more multiresistant than other species (Table 4).
 
DISCUSSION
From the epidemiologic perspective, Shigella is a pathogen 
that persists as a major public health problem in developing 
countries, causing treatment center visits, hospitalizations, 
Table 3. In vitro antimicrobial susceptibility of various species of Shigella isolated from stool cultures at Chil-
dren Medical Center Hospital, Tehran, Iran
Antibiotics                             S. flexneri                          S. sonnei                S. dysenteriae                   S. boydii
 n valid n Valid n valid n valid
  percent  percent  percent  percent
Chloramphenicol 37 32% 136 93% 14 82% 6 75%
Nalidixic acid 162 89% 137 80% 6 38% 6 75%
Tobramycin 138 79% 129 79% 16 80% 7 100%
Gentamicin 152 82% 139 81% 9 45% 8 100%
Amikacin 151 84% 136 81% 7 37% 8 100%
Kanamicin 64 42% 64 39% - - 2 40%
Ampicillin 7 4% 47 27% 18 95% 3 38%
Co-trimoxazole 19 10% 13 8% 18 100% 2 25%
Cephalotine 96 53% 112 66% 19 100% 2 25%
Ceftizoxime 147 90% 167 98% 4 100% 8 100%
Ceftazidime 72 64% 88 87% 16 94% 4 100%
Ceftriaxone 161 94% 158 97% 19 100% 8 100%
and deaths, although it also remains an intermittent cause 
of morbidity and mortality in high risk groups in industrial-
ized countries.
S. sonnei is the predominant Shigella species isolated 
in developed countries,2,6,7 whereas in developing coun-
tries and low socio-economic conditions, S. flexneri 
predominates.1,2,6,8-10 In our study, S. flexneri (48%) was 
the most common, followed by S. sonnei (45%). Other 
species were rare (S. dysenteriae and S. boydii 5% and 2%, 
respectively).
Our isolates are overall most sensitive to ceftriaxone, 
ceftazidime and nalidixic acid (> 84%). They were most re-
sistant to co-trimoxazole and ampicillin (> 86%) which was 
compatible with other studies.1,2,5
Antibiotic susceptibility results are to some extent differ-
ent among different species. S. ﬂ exneri, the most common 
species, was most sensitive to ceftriaxone, ceftizoxime, and 
nalidixic acid; and S. sonnei was most sensitive to ceftizoxi-
me, ceftriaxone, and chloramphenicol. S. ﬂ exneri was more 
sensitive to nalidixic acid than S. sonnei (p-value < 0.05) and 
S. sonnei was more sensitive to cephalosporines (ceftizoxi-
me, ceftriaxone, ceftazidime, cephalotine) than S. ﬂ exneri 
(p-value < 0.05). It shows that for an empiric therapy, when 
the suspected species is S. ﬂ exneri, nalidixic acid will be 
more effective and its resistance trend over the study period 
had not valuable signifi cance, while third cephalosporines 
will be more effective than nalidixic acid in treatment of 
shigellosis due to S. sonnei. S. ﬂ exneri and S. sonnei were 
most resistant to ampicillin and co-trimoxazole. S. ﬂ exneri 
was more resistant to ampicillin than S. sonnei (p-value 
< 0.0001). Other reports from all over the world also indicate 
Table 4. Frequency of multiresistant* Shigella spe-
cies isolated from stool cultures at Children Medical 
Center Hospital, Tehran, Iran
Shigella species Frequency Percent
S. flexneri 158 83%
S. sonnei 106 59%
S. dysenteriae 12 60%
S. boydii 4 50%
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high resistance rates (58.3% to 85%) for ampicillin. Studies 
from Greece12 and Oregon13 did not report species specifi c 
sensitivity, and results from Israel7 have shown similar high 
resistance rates for both S. sonnei and S. ﬂ exneri (87% and 
71%, respectively).2,12-14 The high rate of resistant to ampi-
cillin and co-trimoxazole, which was reported in this study, 
was similar to those reported by the Centers for Disease 
Control and Prevention, NARMS data from 2001 and other 
studies.5,11 In Malaysia, the co-trimoxazole resistance rate of 
S. sonnei was relatively low (37.1%).1 In one study, S. ﬂ exneri 
was much more resistant to chloramphenicol compared with 
S. sonnei.14 This is also in accordance with the other reports. 
One study from Oregon reported a rate of 72% resistance of 
S. ﬂ exneri to chloramphenicol, whereas the resistance of S. 
sonnei was only 1%.13 In our study, all Shigella species were 
sensitive to chloramphenicol, except S. ﬂ exneri, which was 
resistant to it (68%). Ampicillin and chloramphenicol were 
the inexpensive and broad-spectrum antimicrobial agents 
commonly used in developing countries. Increase of resist-
ance to ampicillin or chloramphenicol is often related with 
extensive use of these antimicrobial agents.1
This information is important because S. ﬂ exneri and 
S. sonnei are the most common species and it should be tak-
en into account for treatment. Co-Trimoxazole is a common 
drug used as an empiric therapy in treatment of shigellosis 
and other diarrheal diseases of bacterial origins. The exten-
sive use of this drug has contributed to the emergence of 
resistant S. sonnei and sustained the resistant trait.1,15,16
In addition to co-Trimoxazole and ampicillin, ongoing 
resistance of Shigella species to tetracycline, chlorampheni-
col, and most recently to ﬂ uoroquinolones has been shown. 
Oral aminoglycosides and fi rst and second generation ce-
phalosporins are clinically ineffective, despite their in vitro 
activity.5,17-21 In our study Shigella species were sensitive to 
aminoglycosides, except kanamycin. Kanamycin is a mem-
ber of aminoglycosides, which resistance to it was reported 
before by Lee et al. (2001) and Jeong et al. (2003).22,23 They 
had reported the emergence of kanamycin-resistant S. son-
nei isolates in Korea.1 Although resistance to ﬂ uoroquinolo-
nes has been rarely reported, nearly all Shigella isolates are 
susceptible to these agents. Indeed, quinolones, which are 
also effi cacious against other causes of bacterial gastroen-
teritis, are often recommended as empirical therapy in areas 
with high resistance to Shigella spp. They are, however, not 
approved for children because of the potential risk of dam-
age to growing cartilage.2,6,24 Another suitable antibiotic for 
treatment in children with severe shigellosis, especially in 
those who are hospitalized, is parenteral ceftriaxone, which 
is effective and usually recommended.2 In this study, Shigella 
species (esp. S. dysenteriae and S. boydii) had high sensitivity 
to ceftriaxone.
In milder cases in children, choosing the optimal oral 
therapy is more problematic and should be based on local 
epidemiological data. Nalidixic acid or extended spectrum 
cephalosporins are usually adequate.2 In our study, Shig-
ella species (esp. S. dysenteriae and S. boydii) were highly 
sensitive to third generation cephalosporins (ceftiaxone, 
ceftizoxime, ceftazidime). Despite some studies that has 
reported resistance to nalidixic acid (esp. about S. ﬂ exneri 
and S. dysenteriae),8,9,25 Shigella species were also sensitive to 
nalidixic acid, and S. ﬂ exneri isolates were even more sensi-
tive to it than other species. This data makes nalidixic acid 
still one of the most appropriate antibiotics for treatment of 
shigellosis due to Shigella species’ sensitivity to it, its cost and 
its easy accessibility in Iran. S. dysenteriae causes one of the 
most severe forms of epidemic severe dysenteries.26 It was 
most sensitive to ceftriaxone, ceftizoxime, cephalotine, and 
co-trimoxazole; and most resistant to kanamycin, amikacin 
and nalidixic acid.
Multiresistance to the antimicrobial agents used in treat-
ment of shigellosis has been reported in many parts of the 
world.1,22,23,27,28 In our study, S. ﬂ exneri was more multiresist-
ant than other species, which is very important due to its fre-
quency. Ceftriaxone and ciproﬂ oxacin have been shown to 
be highly effective for shigellosis.5,29-31 Ceftriaxone requires 
parenteral administration, whereas ciproﬂ oxacin is avoided 
in children.
The increasing relative prevalence of Shigella species and 
the emergence of new resistant strains pose a clear public 
health problem. As resistance to antimicrobial agents chang-
es constantly, it is important to keep these strains under 
surveillance in order to monitor the local susceptibility and 
subsequently formulate policies for the rational use of anti-
microbial agents.
REFERENCES 
1. Hoe CH, Yasin RM, Koh YT, Thong KL. Antimicrobial suscep-
tibility and pulsed-fi eld gel electrophoresis of Shigella sonnei 
strains in Malaysia (1997–2000). Applied Microbiology J. 2005; 
99:133-40.
2. Ashkenazi SH, Levy I, Kazaronovski V, Samra Z. Growing anti-
microbial resistance of Shigella isolates. Antimicrobial Chemo-
therapy J. 2003; 51:427-9.
3. National Committee for Clinical Laboratory Standards. Perform-
ance Standards for Antimicrobial Disk Susceptibility Tests: Ap-
proved Standard M2-A7. NCCLS, Villanova, PA, USA. 2000.
4. National Committee for Clinical Laboratory Standards. Meth-
ods for dilution antimicrobial susceptibility tests for bacteria that 
grow aerobically. NCCLS, Wayne, PA, 2000.
5. Jain SK, Gupta A, Glanz B, Dick J, Siberry GK. Antimicrobial-Re-
sistant Shigella sonnei: Limited Antimicrobial Treatment Options 
for Children and Challenges of Interpreting In Vitro Azithromy-
cin Susceptibility. Pediatr Infect Dis J. 2005; 24:494-7.
6. Ashkenazi, S. (1999). Shigella spp. In Antimicrobial Therapy and 
Vaccines (Yu, V. L., Merigan, T. C. & Borriere, S. L., Eds), pp. 382-7. 
Williams & Wilkins, Baltimore, MD, USA.
7. Green MS, Block C, Cohen D, Slater P. Four decades of shigellosis 
in Israel—the epidemiology of a growing public health problem. 
Review of Infectious Diseases. 1991; 13:248-53.
Frequency and antimicrobial susceptibility of Shigella species
157Braz J Infect Dis 2010; 14(2):153-157
8. DuPont, HL (1988). Shigellosis. Infectious Disease Clinics of 
North America 2, 599-605.
9. Pazhani GP, Ramamrthy T, Mitra U, Bhattacharya SK, Niyogi 
SK. Species diversity and antimicrobial resistance of Shigella 
spp. isolated between 2001 and 2004 from hospitalized chil-
dren with diarrhea in Kolkata (Calcutta), India. Epidemiology 
and Infection. 2005; 133:1089-95.
10. Khan A, Huq S, Malek MA et al. Shigella serotypes among hos-
pitalized patients in urban Bangladesh and their antimicrobial 
resistance. Epidemiology and Infection. 2004; 132:773-7
11. Centers for Disease Control and Prevention. NARMS 2001 An-
nual Report: antimicrobial resistance of Salmonella, Shigella, 
and E. coli O157 isolates, 2001. Available at: http://www.cdc.gov/
narms/annual/2001/table/0104.htm. Accessed June 15, 2004.
12. Maraki S, Georgiladakis A, Tselentis Y, Samonis GA. 5 year 
study of the bacterial pathogens associated with acute diarrhea 
on the island of Crete, Greece, and their resistance to antibiot-
ics. Eur J Epidemiol. 2003; 18:85-90.
13. Replogle ML, Fleming DW, Cieslak PR. Emergence of antimi-
crobial- resistant shigellosis in Oregon. Clin Infect Dis. 2000; 
30:515-9.
14. Ozmert EN, Göktürk B, Yurdakök K, Yalçin SS, Gür D. Shigella 
Antibiotic Resistance in Central Turkey: Comparison of the 
Years 1987-1994 and 1995-2002. Pediatric Gastroenterology 
and Nutrition J. 2005; 40:359-62. 
15. Shahid NS, Rahaman MM, Haider K, Banu H, Rahman N. 
Changing pattern of resistant Shigella bacillus (Shigella dys-
enteriae type 1) and Shigella ﬂ exneri in Bangladesh. J Infect 
Dis. 1985; 152:1114-9.
16. Wharton M, Spiegel RA, Horan JM et al. A large outbreak of 
antibiotic-resistant shigellosis at a mass gathering. J Infect Dis. 
1990; 162:1324-8.
17. Islam MR, Alam AN, Hossain MS, Mahalanabis D, Hye HK. 
Double-blind comparison of oral gentamicin and nalidixic 
acid in the treatment of acute shigellosis in children. J Trop 
Pediatr. 1994; 40:320-5.
18. Landa L. Cephradine in the treatment of intestinal infections 
caused by Shigella or Salmonella organisms. Curr Ther Res 
Clin Exp. 1972; 14:496-502.
19. Orenstein WA, Ross L, Overturf GD, Wilkins J, Redfi eld DR, 
Underman A. Antibiotic treatment of acute shigellosis: failure 
of cefamandole compared with trimethoprim/sulfamethoxa-
zole and ampicillin. Am J Med Sci. 1981; 282:27-33.
20. Ostrower VG. Comparison of cefaclor and ampicillin in 
the treatment of shigellosis. Postgrad Med J. 1979;55(suppl 
4):82- 4.
21. Parry HE. Oral kanamycin in the treatment of Shigella and Sal-
monella infections. Postgrad Med J. 1967; suppl:7-13.
22. Lee JC, Oh JY, Kim KS et al. Antimicrobial resistance of Shig-
ella sonnei in Korea during the last two decades. APMIS. 
2001;109:228-34.
23. Jeong YS, Lee JC, Kang HY et al. Epidemiology of nalidixic acid 
resistance and TEM-1- and TEM-52-mediated ampicillin re-
sistance of Shigella sonnei isolates obtained in Korea between 
1980 and 2000. Antimicrob Agents Chemother. 2003; 47:3719-
23
24. Bennish ML, Salam MA. Rethinking options for the treatment 
of shigellosis. Journal of Antimicrobial Chemotherapy. 1992; 
30:243-7.
25. Vasilev V, Japheth R, Yishai R, Andorn N. Antimicrobial resist-
ance of Shigella ﬂ exneri serotypes in Israel during a period 
of three years: 2000-2002. Epidemiology and Infection. 2004, 
132(6):1049-54.
26. Prado V, Lagos R, Nataro JP et al. Population-based study of 
the incidence of Shigella diarrhea and causative serotypes in 
Santiago, Chile. Pediatr Infect Dis J. 1999; 18: 500-5.
27. Ling J, Kam KM, Lam AW, French GL. Susceptibilities of 
Hong Kong isolates of multiply resistant Shigella spp. to 25 
antimicrobial agents, including ampicillin plus sulbactam 
and new 4-quinolones. Antimicrob Agents Chemother. 
1988; 32:20-3.
28. Ashkenazi S, May-Zahav M, Sulkes J, Zilberberg R, Samra Z. 
Increasing antimicrobial resistance of Shigella isolates in Israel 
during the period 1984 to 1992.Antimicrob Agents Chemoth-
er. 1995; 39:819-23. 
29. Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. 
Comparative efficacy of ceftriaxone and ampicillin for 
treatment of severe shigellosis in children. J Pediatr. 1991; 
118:627-632.
30. Leibovitz E, Janco J, Piglansky L et al. Oral ciproﬂ oxacin vs. in-
tramuscular ceftriaxone as empiric treatment of acute invasive 
diarrhea in children. Pediatr Infect Dis J. 2000; 19:1060-7.
31. Eidlitz-Marcus T, Cohen YH, Nussinovitch M, Elian I, Varsano 
I. Comparative effi cacy of two- and fi ve-day courses of ceftri-
axone for treatment of severe shigellosis in children. J Pediatr. 
1993; 123:822-4.
Pourakbari, Mamishi, Mashoori et al.
